ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability.
2015
8066 Background: Rearrangements of the ROS1 oncogene occur in about 1-2% of non-small cell lung cancer (NSCLC) patients. While data suggest that the EML4-ALK/MET/ROS1 inhibitor crizotinib is highly effective in these patients, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. Methods: 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. Results: ROS1 status was analyzed in 1035 (91.0%) patients, whereof 19 (1.8%) had ROS1-rearrangement. The median OS of the patients has not been reached yet. Stage IV patients with ROS1-rearrangement had the best OS of all analyzed subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one re...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI